ToxNav ® validation data published

Today, Oxford Cancer Biomarkers are pleased to announce the publication of the ToxNav ® clinical validation study in the journal

Read More

Oxford Cancer Biomarkers appoints a Medical Science Liaison Manager to strengthen operations and support continued growth

Oxford Cancer Biomarkers (OCB) have made another key appointment. The company has hired a Medical Science Liaison Manager to strengthen

Read More

Oxford Cancer Biomarkers hires two Senior Operations and Quality Control Specialists to help manage continued growth

For immediate release: 22 August 2019 Oxford Cancer Biomarkers (OCB) have hired two Senior Operations and Quality Control Specialists to

Read More

OCB appoints James Otter as new CEO

Oxford, UK, 15th July 2019:    Oxford Cancer Biomarkers has appointed James Otter as Chief Executive Officer. This represents a key growth

Read More

Oxford Cancer Biomarkers Ltd. and Oxford University Hospitals offer genetic testing to prevent 5-FU/capecitabine toxicity

  Oxford, 21st June 2019: Oxford University Hospitals (OUH) NHS Foundation Trust is now offering genetic testing that aims to

Read More

PRESS RELEASE: Oxford, UK and South Korea, 3rd June 2019: KwangDong Pharmaceutical Co. Ltd and Oxford Cancer Biomarkers Ltd. agree a significant investment partnership

Oxford Cancer Biomarkers (OCB) has gained a significant investment from leading South Korean healthcare company KwangDong Pharmaceutical Co. Ltd. (KDP).

Read More

OCB Backing UK’s Artificial Intelligence Revolution

Press Release Oxford Cancer Biomarkers, Tuesday 6th November 2018. OCB is pleased to announce that it is an SME partner

Read More